Dasabuvir: a new direct antiviral agent for the treatment of hepatitis C

Bibliography

• El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012;142(6):1264-73; e1
   PubMed Web of Science ®Google Scholar
• Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 2011;17(2):107-15
   PubMed Web of Science ®Google Scholar
• Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013;57(4):1333-42
   PubMed Web of Science ®Google Scholar
• Negro F. Epidemiology of hepatitis C in Europe. Dig Liver Dis 2014;46S5:S158-S64
   Google Scholar
• Kanwal F, Hoang T, Kramer JR, et al. Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology 2011;140(4):1182-8; e1
   PubMed Web of Science ®Google Scholar
• Westbrook RH, Dusheiko G. Natural history of hepatitis C. J Hepatol 2014;61(1S):S58-68
   Google Scholar
• Kiser JJ, Flexner C. Direct-acting antiviral agents for hepatitis C virus infection. Annu Rev Pharmacol Toxicol 2013;53:427-49
   PubMed Web of Science ®Google Scholar
• Rose L, Bias TE, Mathias CB, et al. Sofosbuvir: a nucleotide NS5B inhibitor for the treatment of chronic hepatitis C infection. Ann Pharmacother 2014;48(8):1019-29
   PubMed Web of Science ®Google Scholar
• Gaetano JN. Benefit-risk assessment of new and emerging treatments for hepatitis C: focus on simeprevir and sofosbuvir. Drug Healthc Patient Saf 2014;6:37-45
   PubMedGoogle Scholar
• Lawitz E, Ghalib R, Rodriguez-Torres M, et al. COSMOS Study: SVR4 results of once-daily regimen of simeprivir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in HCV genotype 1 null responders. 20th Conference on Retroviruses and Opportunistic Infections (CROI); 3 – 6 March 2013; Atlanta, GA; Poster 34
   Google Scholar
• Manns MP, von Hahn T. Novel therapies for hepatitis C - one pill fits all? Nat Rev Drug Discov 2013;12(8):595-610
   PubMed Web of Science ®Google Scholar
• Gentile I, Buonomo AR, Borgia G. Dasabuvir: a non-nucleoside inhibitor of NS5B for the treatment of hepatitis C virus infection. Rev Recent Clin Trials 2014;9:115-23
   PubMedGoogle Scholar
• Kwo PY, Vinayek R. The therapeutic approaches for hepatitis C virus: protease inhibitors and polymerase inhibitors. Gut Liver 2011;5(4):406-17
   PubMed Web of Science ®Google Scholar
• Menon R, Cohen D, Awni W, et al. Pharmacokinetics of the HCV polymerase inhibitor ABT-333 in US and Japanese Healthy Volunteers. J Hepatol 2010;52:S394-S94
   Web of Science ®Google Scholar
• Menon R, Cohen D, Nada A, et al. Pharmacokinetics, safety and tolerability of the HCV Polymerase Inhibitor ABT-333 following multiple ascending doses and effect of co-administration of ketoconazole in healthy subjects. J Hepatol 2009;50:S348-S48
   Web of Science ®Google Scholar
• Maring C, Wagner D, Hutchinson D, et al. Preclinical potency, pharmacokinetic and ADME characterization of ABT-333, a novel non-nucleoside HCV polymerase inhibitor. J Hepatol 2009;50(1):S347
   Web of Science ®Google Scholar
• Rodriguez-Torres M, Lawitz E, Cohen D. Treatment-naive, HCV genotype 1-infected subjects show significantly greater HCV RNA decreases when treated with 28 days of ABT-333 plus peginterferon and ribavirin compared to peginterferon and ribavirin alone. Hepatology 2009;50(Suppl 4):91A
   Google Scholar
• Gaultier I, Cohen D, Dumas E, et al. 12-week efficacy and safety of ABT-072 or ABT-333 with pegylated interferon + ribavirin, following 3-day monotherapy in genotype 1 HCV-infected treatment-naive subjects [abstract 1329]. 21st Conference of the Asian Pacific Association for the Study of the Liver (APASL); 17 – 20 February 2011; Bangkok, Thailand
   Google Scholar
• Pilot-Matias T, Koev G, Krishnan P, et al. In vitro combinatory effect of HCV NS3/4A protease inhibitor ABT-450, NS5A inhibitor ABT-267 and non-nucleoside NS5B polymerase inhibitor ABT-333. J Hepatol 2012;56:S338-S38
   Web of Science ®Google Scholar
• Poordad F, Lawitz E, Kowdley KV, et al. Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med 2013;368(1):45-53
   PubMed Web of Science ®Google Scholar
• Kowdley KV, Lawitz E, Poordad F, et al. Phase 2b trial of interferon-free therapy for hepatitis C Virus genotype 1. N Engl J Med 2014;370(3):222-32
   PubMed Web of Science ®Google Scholar
• Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014;370(17):1594-603
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Jacobson IM, Baykal T, et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014;370(17):1604-14
   PubMed Web of Science ®Google Scholar
• Ferenci P, Nyberg A, Enayati P, et al. PEARL III: 12 weeks of ABT-450/R/267 + ABT-333 achieved SVR in >99% of 419 treatment-naive HCV genotype 1B-infected adults with or without ribavirin. J Hepatol 2014;60(1):S527
   Web of Science ®Google Scholar
• Maieron A, Puoti M, Enejosa J, et al. SVR12 of 99% achieved with a ribavirin-free regimen of ABT-450/r/ombitasvir and dasabuvir in HCV genotype 1b infected patients. ACG Annual Scientific Meeting; 17 – 21 October 2014; Philadelphia, PA; Oral Paper 4
   Google Scholar
• Poordad F, Hezode C, Trinh R, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014;370(21):1973-82
   PubMed Web of Science ®Google Scholar
• Everson G, Lee S, Zeuzem S, et al. Normalization of liver-related laboratory parameters in HCV genotype 1-infected patients with cirrhosis after treatment with ABT-450/R/ombitasvir, dasabuvir and ribavirin. ACG Annual Scientific Meeting. 17 – 21 October 2014; Philadelphia, PA; Oral Paper 5
   Google Scholar
• Kwo PY, Mantry PS, Coakley E, et al. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med 2014;371:2375-82
   PubMed Web of Science ®Google Scholar
• Eron JJ, Lalezari J, Slim J, et al. Safety and efficacy of ombitasvir - 450/r and dasabuvir and ribavirin in HCV/HIV-1 co-infected patients receiving atazanavir or raltegravir ART regimens. J Int AIDS Soc 2014;17(4 Suppl 3):19500
   PubMed Web of Science ®Google Scholar
• Cohen D, Xie W, Larsen L, et al. Safety of ribavirin-containing regimens of ABT-450/r, ABT-333, and ABT-267 for the treatment of HCV zenotype 1 infection and efficacy in subjects with ribavirin dose reductions. Hepatology 2013;S1:140A
   Google Scholar
• Rodriguez-Torres M, Nunes F, Cohen D, et al. Interferon-free regimens of ABT-450/r, ABT-267, ABT-333, and ribavirin achieve high sustained virologic response 4 weeks post-treatment rates in patients with chronic HCV genotype 1 regardless of race, ethnicity, or other baseline characteristics [abstract 514]. DDW; 18 – 21 May 2013; Orlando, FL
   Google Scholar
• Ferenci P, Bernstein D, Lalezari J, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 2014;370(21):1983-92
   PubMed Web of Science ®Google Scholar
• Zhou S. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr Drug Metab 2008;9(4):310-22
   PubMed Web of Science ®Google Scholar
• Zhou S, Xue C, Yu X, et al. Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther Drug Monit 2007;29(6):687-710
   PubMed Web of Science ®Google Scholar
• Koev G, Mondal R, Beyer J, et al. Characterization of resistant mutations selected in vitro by the non-nucleoside HCV polymerase inhibitors ABT-333 and ABT-072. J Hepatol 2009;50:S346-S47
   Web of Science ®Google Scholar
• Middleton T, He Y, Beyer J, et al. Resistance profile of ABT-333 and relationship to viral load decrease in patients treated in combination with peg-interferon and ribavirin for 28 days. J Hepatol 2010;52:S296-S97
   PubMed Web of Science ®Google Scholar
• Pilot-Matias T, Tripathi RL, Koev G, et al. Characterization of resistant variants in NS3 and NS5B detected in subjects treated with ABT-450/r, ribavirin, and either ABT-072 or ABT-333 in the pilot and co-pilot studies who experienced virologic breakthrough or relapse. Hepatology 2012;56:569A-70A
   Web of Science ®Google Scholar